6:00 PM
 | 
Jul 22, 2009
 |  BC Extra  |  Company News

NICE issues Viread, MabThera guidance

The U.K.'s NICE issued final guidance for two drugs: Viread tenofovir from Gilead Sciences Inc. (NASDAQ:GILD) and MabThera (Rituxan-U.S.) rituximab from Roche...

Read the full 109 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >